Trials / Completed
CompletedNCT06738511
Validation of a Molecular Signature for Early Detection of Colorectal Cancer
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 3,421 (actual)
- Sponsor
- ADVANCED MARKER DISCOVERY S.L. · Industry
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The goal of this Multicentre and international prospective study is to validate a molecular signature using plasma samples in average-risk population for colorectal cancer who undergo colonoscopy in a screening setting. The main question it aims to answer is: Does molecular signature in plasma sample have higher diagnostic accuracy than FIT for early detection of colorectal cancer? Participants who already have a colonoscopy as part of their regular medical care for colorectal cancer screening will provide a stool sample and a plasma sample.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | blood sampling | Molecular signature using plasma sample |
| OTHER | stool sampling | Stool sampling (by the participant) |
| OTHER | colonoscopy | Colonoscopy will be performed in the course of a screening programme |
Timeline
- Start date
- 2018-05-28
- Primary completion
- 2021-09-01
- Completion
- 2021-09-01
- First posted
- 2024-12-17
- Last updated
- 2024-12-17
Locations
2 sites across 2 countries: Germany, Poland
Source: ClinicalTrials.gov record NCT06738511. Inclusion in this directory is not an endorsement.